FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers - FDA.gov

Investor's Business Daily

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers FDA.gov The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have ... After-hours buzz: RHT, DRI, TSRO & moreCNBC FDA approves Zejula for maintenance treatment of gynecologic cancersHealio Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian CancerTheStreet.com Curetoday.com -MedPage Today -Pharmacy Times -The Boston Globe all 40 news articles »

from Health - Google News http://ift.tt/2nbCArS